This mutation affects cellular signaling, leading to uncontrolled cell proliferation and tumor formation, especially in approximately 85% of pancreatic ductal adenocarcinomas (PDACs), 45% of colorectal adenocarcinomas and 30% of lung adenocarcinomas.[9] Tumors with Kras mutations tend to be more aggressive and may be less responsive to certain treatments, including targeted therapies.[10] Ongoing research aims to better understand these mutations and develop specific therapies to address tumors with mutated Kras, thereby improving treatment options for cancer patients.[11]. Here, KRAS is linked to pancreatic ductal adenocarcinoma.